Propionic acid and fasudil as treatment against rotenone toxicity in an in vitro model of Parkinson's disease
Open accessThe DOI matches its Crossref record; 55 of the 57 references it cites were found in a registry or an index.
Abstract
Parkinson’s disease (PD) is a multifactorial neurodegenerative disease. In recent years, several studies demonstrated that the gastroenteric system and intestinal microbiome influence central nervous system function. The pathological mechanisms triggered thereby change neuronal function in neurodegenerative diseases including dopaminergic neurons in Parkinson´s disease. In this study, we employed a model system for PD of cultured primary mesencephalic cells and used the pesticide rotenone to model dopaminergic cell damage. We examined neuroprotective effects of the Rho kinase inhibitor Fasudil and the short chain fatty acid (SCFA) propionic acid on primary neurons in cell morphological assays, cell survival, gene and protein expression. Fasudil application resulted in significantly enhanced neuritic outgrowth and increased cell survival of dopaminergic cells. The application of propionic acid primarily promoted cell survival of dopaminergic cells against rotenone toxicity and increased neurite outgrowth to a moderate extent. Interestingly, Fasudil augmented gene expression of synaptophysin whereas gene expression levels of tyrosine hydroxylase (TH) were substantially increased by propionic acid. Concerning protein expression propionic acid treatment increased STAT3 levels but did not lead to an increased phosphorylation indicative of pathway activation. Our findings indicate that both Fasudil and propionic acid treatment show beneficial potential in rotenone-lesioned primary mesencephalic cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A recent study on the effect of propionate on rotenone-treated dopaminergic neurons showed that the survival rate of TH + dopaminergic neurons increased significantly, indicating that propionic acid increased the expression of the TH gene, decreased the expression of the a-synuclein gene, and increased the expression of intracellular STAT3 protein to promote neuroprotection.197”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as [197]
Experimental — accuracy not yet measuredIn the citing paper
“propionate supplementation was able to promote neurite outgrowth, tyrosine hydroxylase (TH) expression and dopaminergic cell survival in vitro [112]”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“Since the publication of the Braak hypothesis of aSyn propagation from gut to brain [6], the gut–brain-axis has become an important focus of PD research.”
BackgroundKalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622 · cited 2×
“In in vivo models of PD, an increase in microglia activation was observed after enhancement of aSyn-mediated pathology by SCFA [10].”
BackgroundThe Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication
Silva, Y. P., Bernardi, A., & Frozza, R. L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00025 · Cited by 3,043 · cited 3×
“Besides its promoting effect on neural progenitor cells [30], the direct impact on SCFA on neurons is poorly investigated, but an influence of neurotransmitter synthesis and levels of neurotrophic factors has been observed [22].”
BackgroundMethodColonic Health: Fermentation and Short Chain Fatty Acids
Wong, J. M. W., de Souza, R., Kendall, C. W. C., Emam, A., & Jenkins, D. J. A. (2006) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200603000-00015 · Cited by 2,739 · cited 2×
“SCFA are produced by anaerobic bacteria like Fusobacterium through the fermentation of dietary carbohydrates such as dietary fibers [12,13].”
BackgroundGut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968 · cited 1×
“Clinical studies show alteration in the microbiome in fecal samples of PD patients compared to healthy controls [7].”
BackgroundRegulation of inflammation by short chain fatty acids
Vinolo, M. A. R., Rodrigues, H. G., Nachbar, R. T., & Curi, R. (2011) · Nutrients · doi:10.3390/nu3100858 · Cited by 1,724 · cited 2×
“SCFA as has been Molecules 2020, 25, 2502 10 of 15 demonstrated to influence inflammatory cells like microglia or leukocytes and effect the production of pro- and anti-inflammatory cytokines like interleukin 10 (IL-10) or tumor necrosis factor alpha (TNFα) [47,51].”
BackgroundLi, N., Ragheb, K., Lawler, G., Sturgis, J., Rajwa, B., Melendez, J. A., & Robinson, J. P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210432200 · Cited by 1,433 · cited 3×
“Rotenone inhibits the mitochondrial respiratory chain which leads to decreased adenosine triphosphate (ATP) levels, oxidative stress through reactive oxygen species (ROS) and ultimately to neurite damage and apoptosis.”
BackgroundUnger, M. M., Spiegel, J., Dillmann, K.-U., Grundmann, D., Philippeit, H., Bürmann, J., Faßbender, K., Schwiertz, A., & Schäfer, K.-H. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.08.019 · Cited by 1,159
Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases
Erkkinen, M. G., Kim, M.-O., & Geschwind, M. D. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033118 · Cited by 1,124 · cited 1×
“Parkinson’s disease (PD) is the second most common neurodegenerative disease [1].”
BackgroundMechanism of Toxicity in Rotenone Models of Parkinson's Disease
Sherer, T. B., Betarbet, R., Testa, C. M., Seo, B. B., Richardson, J. R., Kim, J. H., Miller, G. W., Yagi, T., Matsuno-Yagi, A., & Greenamyre, J. T. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-34-10756.2003 · Cited by 1,072 · cited 4×
“Rotenone inhibits the mitochondrial respiratory chain which leads to decreased adenosine triphosphate (ATP) levels, oxidative stress through reactive oxygen species (ROS) and ultimately to neurite damage and apoptosis.”
BackgroundInfluentialParkinson's disease: a dual‐hit hypothesis
Hawkes, C. H., Del Tredici, K., & Braak, H. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2007.00874.x · Cited by 1,021
Cabin, D. E., Shimazu, K., Murphy, D., Cole, N. B., Gottschalk, W., McIlwain, K. L., Orrison, B., Chen, A., Ellis, C. E., Paylor, R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-20-08797.2002 · Cited by 865 · cited 1×
“The physiological function of endogenous aSyn is not completely understood but it is suggested to regulate presynaptic vesicles [38,39] and to influence vesicular dynamics in cells [40,41].”
BackgroundMurphy, D. D., Rueter, S. M., Trojanowski, J. Q., & Lee, V. M.-Y. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-09-03214.2000 · Cited by 836 · cited 1×
“The physiological function of endogenous aSyn is not completely understood but it is suggested to regulate presynaptic vesicles [38,39] and to influence vesicular dynamics in cells [40,41].”
BackgroundNon‐motor symptoms in Parkinson’s disease
Poewe, W. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02056.x · Cited by 782 · cited 1×
“Interestingly, non-motor symptoms like hyposmia or depression often manifest already before motor symptoms arise [2,3].”
BackgroundPerucca, E. (2002) · CNS Drugs · doi:10.2165/00023210-200216100-00004 · Cited by 690 · cited 1×
“Furthermore, SCFA are already used in other neurological diseases like valproic acid is used as anti-epileptic drug since 1967 [45].”
BackgroundPropionic Acid Shapes the Multiple Sclerosis Disease Course by an Immunomodulatory Mechanism
Duscha, A., Gisevius, B., Hirschberg, S., Yissachar, N., Stangl, G. I., Dawin, E., Bader, V., Haase, S., Kaisler, J., David, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.035 · Cited by 644 · cited 4×
“In a recent application study in human multiple sclerosis patients, propionic acid substantially increased regulatory T cells and decreased pro-inflammatory Th1 and Th17 cells in serum and feces which was associated with a more beneficial course of disease [47].”
BackgroundSelf-citationPathogenesis of Parkinson disease—the gut–brain axis and environmental factors
Klingelhoefer, L., & Reichmann, H. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.197 · Cited by 598 · cited 1×
“Interestingly, non-motor symptoms like hyposmia or depression often manifest already before motor symptoms arise [2,3].”
BackgroundMicrobiome–host systems interactions: protective effects of propionate upon the blood–brain barrier
Hoyles, L., Snelling, T., Umlai, U.-K., Nicholson, J. K., Carding, S. R., Glen, R. C., & McArthur, S. (2018) · Microbiome · doi:10.1186/s40168-018-0439-y · Cited by 591 · cited 1×
“Besides direct effects in the gut, SCFA are detectable in the peripheral blood and are suggested to directly influence the blood–brain barrier [15].”
BackgroundThe Synaptic Function of α-Synuclein
Burré, J. (2015) · Journal of Parkinson's Disease · doi:10.3233/jpd-150642 · Cited by 573 · cited 1×
“The physiological function of endogenous aSyn is not completely understood but it is suggested to regulate presynaptic vesicles [38,39] and to influence vesicular dynamics in cells [40,41].”
BackgroundGhaisas, S., Maher, J., & Kanthasamy, A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.012 · Cited by 521 · cited 1×
“SCFA are produced by anaerobic bacteria like Fusobacterium through the fermentation of dietary carbohydrates such as dietary fibers [12,13].”
BackgroundMACFABE, D., CAIN, D., RODRIGUEZCAPOTE, K., FRANKLIN, A., HOFFMAN, J., BOON, F., TAYLOR, A., KAVALIERS, M., & OSSENKOPP, K. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.07.025 · Cited by 497
Parkinson disease and the immune system - Associations, mechanisms and therapeutics
Tan, E.-K., Chao, Y.-X., West, A., Chan, L.-L., Poewe, W., & Jankovic, J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0344-4 · Cited by 457 · cited 2×
“Several preclinical and clinical studies underline the impact of immunological dysregulations like inflammatory cell activation on PD [48].”
BackgroundPesticide exposure and risk for Parkinson's disease
Ascherio, A., Chen, H., Weisskopf, M. G., O'Reilly, E., McCullough, M. L., Calle, E. E., Schwarzschild, M. A., & Thun, M. J. (2006) · Annals of Neurology · doi:10.1002/ana.20904 · Cited by 445 · cited 1×
“In contrast to MPP+, rotenone has been shown to facilitate aggregation of aSyn [19] and is a known environmental risk factor for PD [20,21].”
BackgroundLangston, J. W. (2017) · Journal of Parkinson’s Disease · doi:10.3233/jpd-179006 · Cited by 424
Short-Chain Fatty Acids Improve Poststroke Recovery via Immunological Mechanisms
Sadler, R., Cramer, J. V., Heindl, S., Kostidis, S., Betz, D., Zuurbier, K. R., Northoff, B. H., Heijink, M., Goldberg, M. P., Plautz, E. J., et al. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.1359-19.2019 · Cited by 335 · cited 1×
“Furthermore, post-stroke recovery in a mice model was improved by SCFA treatment through increased spine and synapse densities and improved connectivity but also immunological mechanisms like microglia activation [46].”
BackgroundTh17 lymphocytes induce neuronal cell death in a human iPSC-based model of Parkinson's disease
Sommer, A., Marxreiter, F., Krach, F., Fadler, T., Grosch, J., Maroni, M., Graef, D., Eberhardt, E., Riemenschneider, M. J., Yeo, G. W., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.06.015 · Cited by 332 · cited 1×
“For example, increased pro-inflammatory Th17 cells can be observed in PD mouse models and human blood and port-mortem brains of PD patients [49,50].”
BackgroundNankova, B. B., Agarwal, R., MacFabe, D. F., & La Gamma, E. F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103740 · Cited by 294 · cited 1×
“SCFA seem to affect the neurotransmitter synthesis in dopaminergic neurons through regulation of tryptophan 5-hydroxylase 1 and increase TH levels [22,36].”
Backgroundα-Synuclein Inhibits Intersynaptic Vesicle Mobility and Maintains Recycling-Pool Homeostasis
Scott, D., & Roy, S. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0535-12.2012 · Cited by 243
ROCK inhibition in models of neurodegeneration and its potential for clinical translation
Koch, J. C., Tatenhorst, L., Roser, A.-E., Saal, K.-A., Tönges, L., & Lingor, P. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.03.008 · Cited by 239 · cited 1×
“Inhibition of ROCK has shown to mediate neuritic outgrowth, axonal regeneration, neuronal cell growth, and neuroprotection due to reduced induction of apoptosis [24].”
BackgroundSelf-citationNeuropathological basis of nonmotor manifestations of Parkinson's disease
Adler, C. H., & Beach, T. G. (2016) · Movement Disorders · doi:10.1002/mds.26605 · Cited by 230 · cited 1×
“Gastrointestinal dysfunctions such as constipation are other common manifestations [4].”
BackgroundShultz, S. R., MacFabe, D. F., Ossenkopp, K.-P., Scratch, S., Whelan, J., Taylor, R., & Cain, D. P. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.01.013 · Cited by 217
Leng, Y., & Chuang, D.-M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0096-06.2006 · Cited by 188 · cited 1×
“The potential of SCFA to induce aSyn aggregation in vivo [10] and to increase expression of endogenous aSyn in neurons [37] has been previously described.”
BackgroundTonges, L., Frank, T., Tatenhorst, L., Saal, K. A., Koch, J. C., Szego, E. M., Bahr, M., Weishaupt, J. H., & Lingor, P. (2012) · Brain · doi:10.1093/brain/aws254 · Cited by 176 · cited 8×
“An often-used toxin is 1-methyl-4-phenylpyridinum (MPP+), which is selectively taken up by dopaminergic cells, where it concentrates in mitochondria and leads to inhibition of the electron transfer chain [16].”
BackgroundHistone deacetylase inhibitors: possible implications for neurodegenerative disorders
Hahnen, E., Hauke, J., Tränkle, C., Eyüpoglu, I. Y., Wirth, B., & Blümcke, I. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.2.169 · Cited by 165 · cited 1×
“Due to its inhibiting effects on histone deacetylase (HDAC), which lead to inhibition of gene transcription, SCFA show beneficial effects in neurodegenerative diseases such as Alzheimer’s disease [43,44].”
BackgroundFasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
Tatenhorst, L., Eckermann, K., Dambeck, V., Fonseca-Ornelas, L., Walle, H., Lopes da Fonseca, T., Koch, J. C., Becker, S., Tönges, L., Bähr, M., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0310-y · Cited by 158
Self-citationEnteric short‐chain fatty acids promote proliferation of human neural progenitor cells
Yang, L. L., Millischer, V., Rodin, S., MacFabe, D. F., Villaescusa, J. C., & Lavebratt, C. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.14928 · Cited by 157 · cited 2×
“Besides its promoting effect on neural progenitor cells [30], the direct impact on SCFA on neurons is poorly investigated, but an influence of neurotransmitter synthesis and levels of neurotrophic factors has been observed [22].”
BackgroundDiet in Parkinson’s Disease: Critical Role for the Microbiome
Jackson, A., Forsyth, C. B., Shaikh, M., Voigt, R. M., Engen, P. A., Ramirez, V., & Keshavarzian, A. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01245 · Cited by 145 · cited 1×
“In contrast to MPP+, rotenone has been shown to facilitate aggregation of aSyn [19] and is a known environmental risk factor for PD [20,21].”
BackgroundAbdelli, L. S., Samsam, A., & Naser, S. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-45348-z · Cited by 144
Srivastava, P., & Panda, D. (2007) · The FEBS Journal · doi:10.1111/j.1742-4658.2007.06004.x · Cited by 138 · cited 1×
“Rotenone has been shown to have inhibiting effects on microtubule assembly in in vitro experiments [32].”
BackgroundFatty acids and their therapeutic potential in neurological disorders
Lei, E., Vacy, K., & Boon, W. C. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.02.014 · Cited by 138 · cited 1×
“Due to its inhibiting effects on histone deacetylase (HDAC), which lead to inhibition of gene transcription, SCFA show beneficial effects in neurodegenerative diseases such as Alzheimer’s disease [43,44].”
BackgroundYuan, Y., Yan, W.-F., Sun, J., Huang, J., Mu, Z., & Chen, N. (2014) · Toxicology Letters · doi:10.1016/j.toxlet.2014.11.029 · Cited by 124 · cited 1×
“In contrast to MPP+, rotenone has been shown to facilitate aggregation of aSyn [19] and is a known environmental risk factor for PD [20,21].”
BackgroundPlasma Short‐Chain Fatty Acids in Patients With Parkinson's Disease
Shin, C., Lim, Y., Lim, H., & Ahn, T. (2020) · Movement Disorders · doi:10.1002/mds.28016 · Cited by 116 · cited 1×
“In a recent analysis of the plasma concentration of propionic acid in PD patients, low propionic acid levels correlated with worse motor function as measured with the Unified Parkinson’s Disease Rating Score part III (UPDRS-III) [52].”
MethodLiu, Z., Huang, Y., Cao, B.-B., Qiu, Y.-H., & Peng, Y.-P. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0249-9 · Cited by 112 · cited 1×
“For example, increased pro-inflammatory Th17 cells can be observed in PD mouse models and human blood and port-mortem brains of PD patients [49,50].”
BackgroundLin, C., Huang, J.-Y., Ching, C., & Chuang, J. (2007) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2007.00510.x · Cited by 92 · cited 1×
“Other studies showed that, DAT protein expression was downregulated in in vivo experiments with rotenone in rats [31].”
BackgroundBonnet, U., Bingmann, D., & Wiemann, M. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)00063-2 · Cited by 88 · cited 1×
“Because of its potential to cross the blood–brain barrier [23], we examined the direct effect of propionic acid on neuronal cells of the central nervous system.”
BackgroundYuan, J., Jinpeng, R., Wang, Y., He, X. D., & Zhao, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162696 · Cited by 60
Zhao, Y., Zhang, Q., Xi, J., Li, Y., Ma, C., & Xiao, B. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.03.022 · Cited by 58 · cited 1×
“In previous studies, it could be shown that ROCK inhibition is also pro-regenerative in other toxin-based models such as MPTP/MPP+ based in vitro and in vivo experiments [25,29].”
BackgroundA controversy on the role of short-chain fatty acids in the pathogenesis of Parkinson's disease
Mulak, A. (2018) · Movement Disorders · doi:10.1002/mds.27304 · Cited by 45 · cited 1×
“Propionic acid was used as a potential regenerative treatment, as SCFAs have already been discussed for their influence on immune reactions in the gut [9] and have been demonstrated to elicit a direct effect on neurons after passing the blood–brain barrier [22].”
MethodMouhape, C., Costa, G., Ferreira, M., Abin‐Carriquiry, J. A., Dajas, F., & Prunell, G. (2018) · Neurotoxicity Research · doi:10.1007/s12640-018-9931-1 · Cited by 44 · cited 1×
“This is in line with other studies that have employed rotenone on primary dopaminergic cell cultures [27,28].”
ResultRole of Rho Kinase and Fasudil on Synaptic Plasticity in Multiple Sclerosis
Chen, C., Yu, J., Zhang, Q., Zhao, Y., Liu, C., Lǐ, Y., Yang, W., Ma, C., & Xiao, B. (2015) · NeuroMolecular Medicine · doi:10.1007/s12017-015-8374-6 · Cited by 28 · cited 1×
“While Fasudil had no beneficial influence on DAT, MAP2 or TH gene expression under rotenone stress, it significantly reduced the effect of rotenone on SYP and therefore implies a protective effect on the synaptic integrity [35].”
BackgroundSerrano‐García, N., Fernández‐Valverde, F., Luis‐García, E. R., Granados-Rojas, L., Juárez-Zepeda, T. E., Orozco-Suárez, S. A., Pedraza‐Chaverrí, J., Orozco‐Ibarra, M., & Jiménez‐Anguiano, A. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.10.015 · Cited by 26 · cited 1×
“Decrease of SYP expression has already been described in in vivo experiments with rotenone treated rats [34].”
BackgroundImpact of Propionic Acid on Liver Damage in Rats.
Al-Daihan, S., & Bhat, R. S. (2015) · PubMed Central · Cited by 25
Radad, K., Moldzio, R., & Rausch, W.-D. (2015) · Folia Neuropathologica · doi:10.5114/fn.2015.54426 · Cited by 24 · cited 1×
“This is in line with other studies that have employed rotenone on primary dopaminergic cell cultures [27,28].”
Result
Cited by
Short chain fatty acids: Microbial metabolites for gut-brain axis signalling
O'Riordan, K. J., Collins, M. K., Moloney, G. M., Knox, E. G., Aburto, M. R., Fülling, C., Morley, S. J., Clarke, G., Schellekens, H., & Cryan, J. F. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111572 · Cited by 713
Role of microbiota-derived short-chain fatty acids in nervous system disorders
Mirzaei, R., Bouzari, B., Hosseini-Fard, S. R., Mazaheri, M., Ahmadyousefi, Y., Abdi, M., Jalalifar, S., Karimitabar, Z., Teimoori, A., Keyvani, H., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111661 · Cited by 386
Gut Microbiota Dysbiosis: Pathogenesis, Diseases, Prevention, and Therapy
Shen, Y., Fan, N., Ma, S., Cheng, X., Yang, X., & Wang, G. (2025) · MedComm · doi:10.1002/mco2.70168 · Cited by 301
The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options
Wang, Q., Luo, Y., Ray Chaudhuri, K., Reynolds, R., Tan, E.-K., & Pettersson, S. (2021) · Brain · doi:10.1093/brain/awab156 · Cited by 281
Feeding gut microbes to nourish the brain: unravelling the diet–microbiota–gut–brain axis
Schneider, E., O’Riordan, K. J., Clarke, G., & Cryan, J. F. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01108-6 · Cited by 272
“Addressing this deficit, propionate treatment promoted dopaminergic cell survival in an in vitro PD mouse model 134 .”
Metadata
- Authors
- Ostendorf, F., Metzdorf, J., Gold, R., Haghikia, A., & Tönges, L.
- Affiliations
- St. Josef-Hospital (DE)
- Corresponding author
- Tönges, Lars
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-05-28
- Volume
- 25
- Issue
- 11
- Pages
- 2502
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7321113
- OpenAlex
- W3031730348
- Semantic Scholar
- 1be7d31728d0df084db15e3c8ed9ffec5a96f339
- Cited by
- 46
- References
- 57
- Citations by year
- 2025: 12 · 2024: 12 · 2023: 7 · 2022: 8 · 2021: 6 · 2020: 1
- FWCI
- 2.38
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dokumentenrepositorium der RUB (Ruhr University Bochum) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Deutsche Forschungsgemeinschaft
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Keywords
- Parkinson's disease, rotenone toxicity, fasudil, propionic acid, short-chain fatty acids, Rho kinase inhibition, dopaminergic neurons, neuroprotection, neurite outgrowth, synaptophysin, tyrosine hydroxylase, STAT3, gut-brain axis, gut microbiota
- MeSH terms
- Animals, Cell Survival, Cells, Cultured, Female, Immunohistochemistry, Parkinson Disease, Pregnancy, Propionates, Rotenone, Tyrosine 3-Monooxygenase, Blotting, Western, Rats, Sprague-Dawley, Neuroprotective Agents, 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine, Rats, rho-Associated Kinases, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.